Paul Kidwell
Biotech/Pharma PR Professional

About

Since 2002, Paul Kidwell has applied his strategic
PR consulting expertise to numerous biotechnology, pharmaceutical, healthcare and medical device companies; providing targeted media relations as well as other communications services in support of major business and scientific milestones.

 

During this time, Paul has worked on behalf of early-stage biotechnology organizations and more established biopharmaceutical companies, applying his unique brand of PR and ensuring that his communications effort works in concert with the specific demands of a company at each development stage.

 

Paul offers each life science clients a tailored communications approach that supports specific business and communications goals at particular times of a company's growth. Whether it's introducing an early-stage biotech and its pre-clinical science, supporting a patent advocacy program through targeted national and/or local market media relations, or reaffirming an established biopharmaceutical company's therapeutic expertise by assuring news coverage at a medical meeting, Paul implements a tactical strategy that is both precise and deep.

 

Paul has worked clients that are wide-ranging in size of pipeline and stage of development. Emerging biotech companies use his established skills to help them gain a foothold both in financial markets, attract investors and business partners, and secure  premier scientists and business people as future employees. Established,  publicly-traded pharmaceutical companies take advantage of Paul's ability to successfully guide a corporate news program and secure coverage in top tier business press, scientific media, and when appropriate, local market daily and business journals. He has extensive experience supporting companies that are developing drugs to treat cancer, cardiovascular disease, select neurological illnesses, infectious disease, diabetes, inflammation, and rare diseases.

 

Before establishing his independent PR consultancy, Paul held senior communications positions with biotechnology and high-technology companies, as well as PR agencies doing work for clients within those same market sectors.